Evidence map›Paper›PMID 35144387›Full record

ReviewChinese clinical oncology2022

Artificial intelligence and imaging for risk prediction of pancreatic cancer: a narrative review.

Touseef Ahmad Qureshi, Sehrish Javed, Tabasom Sarmadi, Stephen Jacob Pandol, Debiao Li

Abstract readReview
In one paragraph

Review in Chinese clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Touseef Ahmad QureshiBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sehrish JavedBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Tabasom SarmadiRegis University, Colorado, USA.
Stephen Jacob PandolBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Debiao LiBiomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

Predicting Pancreatic Ductal Adenocarcinoma PDAC Through Artificial Intelligence Analysis of Pre Diagnostic CT Images in African AmericansR01CA260955 · NCI · CEDARS-SINAI MEDICAL CENTER · PI LI, DEBIAO, PANDOL, STEPHEN J. · 2021 to 2025
$4.8M
NCI NIH HHS R01 CA260955
6 · The paper itself

Abstract

objectiveTo emphasize the importance of pancreatic imaging and the application of artificial intelligence (AI) for enhanced risk prediction of pancreatic ductal adenocarcinoma (PDAC).

backgroundDetecting PDAC at the early stage is challenging as the disease either remains asymptomatic or presents nonspecific symptoms. Risk prediction of PDAC is an efficient strategy as subsequent targeted screening can assist in diagnosing cancer at the early stage even before the symptoms appear. However, the lack of specific clinical and epidemiological predictors of PDAC makes prediction a highly challenging task. Detecting precursor changes in the pancreas can potentially assist in the risk prediction of PDAC as the precancerous pancreas evolves through biological adaptations-presented as morphological and textural changes on abdominal imaging. However, such microlevel "clues" usually remain unnoticed or unappreciated, partly due to the unavailability of tools to detect and interpret such complex measurements, making the risk prediction of PDAC an unresolved problem.

methodsThis review study highlights the limitations of the current risk prediction models of PDAC and the importance of abdominal imaging for predicting PDAC. A suggestive narrative is made as to how recent AI tools can assist in extracting precise measurements of biomarkers, detecting early signs and precancerous abnormalities, quantifying tissue characteristics, and revealing complex features potentially indicative of future incidence of pancreatic cancer (PC) using abdominal imaging. With the help of peer examples of other cancers, a case is built about the application of AI in utilizing image features of the pancreas to enhance risk prediction of PDAC. Furthermore, the challenges of AI applications including insufficient data for model training, risk of data privacy violation, inconsistent data labeling, and limited computational resources, and their potential solutions are also discussed.

conclusionsThe recent advancement in the domain of AI is a potential opportunity to utilize automated tools for the identification of imaging-based indicators of PDAC and perform enhanced risk prediction of cancer. With this awareness and motivation, better management of PDAC has expected.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsArtificial IntelligenceDiagnostic ImagingHumansabdominal imagingpancreatic cancer (PC)Risk prediction

Identifiers

PMID35144387
PMCPMC9273027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.